| 7.04 0.05 (0.72%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.67 | 1-year : | 9.62 |
| Resists | First : | 7.42 | Second : | 8.24 |
| Pivot price | 7.2  |
|||
| Supports | First : | 6.1 | Second : | 5.07 |
| MAs | MA(5) : | 7.01 |
MA(20) : | 7.12 |
| MA(100) : | 6.44 |
MA(250) : | 6.17 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 50.9 |
D(3) : | 53.1 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 8.24 | Low : | 4.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TENX ] has closed above bottom band by 26.9%. Bollinger Bands are 5.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.2 - 7.23 | 7.23 - 7.26 |
| Low: | 6.74 - 6.77 | 6.77 - 6.81 |
| Close: | 6.98 - 7.04 | 7.04 - 7.1 |
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Fri, 07 Nov 2025
Tenax Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview - TradingView
Thu, 06 Nov 2025
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 for the Treatment of PH-HFpEF - Investing News Network
Thu, 06 Nov 2025
Tenax (Nasdaq: TENX) sets Nov 13 virtual KOL webcast on TNX-103 for PH-HFpEF - Stock Titan
Thu, 06 Nov 2025
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF - GlobeNewswire
Mon, 03 Nov 2025
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - Investing News Network
Mon, 03 Nov 2025
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 95.4 (%) |
| Shares Short | 754 (K) |
| Shares Short P.Month | 275 (K) |
| EPS | 2.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.7 % |
| Return on Equity (ttm) | -56.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | 2.39 |
| PEG Ratio | 0 |
| Price to Book value | 2.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|